BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

...data in the NDA are of "unclear clinical significance," despite showing patients who received the melatonin...
BioCentury | Mar 9, 2018
Clinical News

Vanda's Hetlioz meets in Phase III for jet lag disorder

...details. In 2004, Bristol-Myers Squibb Co. (NYSE:BMY) granted Vanda exclusive, worldwide rights to Hetlioz. The melatonin...
...Product: Hetlioz tasimelteon (VEC-162) Business: Neurology Molecular target: Melatonin MT1 receptor; melatonin MT2 receptor Description: Melatonin...
...analog scale (VAS) Status: Phase III data Milestone: NA Chris Lieu Hetlioz tasimelteon VEC-162 Bristol-Myers Squibb Co. Vanda Pharmaceuticals Inc. Melatonin MT1 receptor Melatonin...
BioCentury | Feb 16, 2018
Clinical News

Neurim's PedPRM meets in Phase III for insomnia in children with autism

...Pharmaceuticals Ltd., Tel Aviv, Israel Product: PedPRM melatonin Business: Neurology Molecular target: Melatonin MT1 receptor; Melatonin...
...Business: Neurology Molecular target: Melatonin MT1 receptor; Melatonin MT2 receptor Description: Pediatric prolonged-release formulation of melatonin...
...and satisfaction of child’s sleep Status: Phase III data Milestone: NA Claire Quang Neurim Pharmaceuticals Ltd. Melatonin MT1 receptor Melatonin...
BioCentury | Oct 10, 2016
Clinical News

Piromelatine: Phase II started

...Neu-P11 ) Business: Neurology Molecular target: Melatonin MT1 receptor ; Serotonin (5-HT1A) receptor Description: Melatonin...
BioCentury | Jul 13, 2015
Clinical News

Hetlioz tasimelteon regulatory update

...Vanda for Hetlioz tasimelteon to treat non-24-hour sleep-wake disorder in blind adults. FDA approved the melatonin...
BioCentury | Apr 27, 2015
Clinical News

Hetlioz tasimelteon regulatory update

...Hetlioz tasimelteon from Vanda to treat non-24-hour sleep-wake disorder in blind adults. FDA approved the melatonin...
BioCentury | Apr 25, 2015
Company News

CHMP backs Opdivo and Hetlioz, spurns Lympreva

...Ono and BMS are partnered. CHMP also recommended approval of Vanda's Hetlioz tasimelteon , a melatonin...
BioCentury | Oct 30, 2014
Financial News

Vanda raises $58M in follow-on

...it would use the proceeds to commercialize Hetlioz tasimelteon in the U.S. FDA approved the melatonin...
BioCentury | Sep 22, 2014
Company News

Takeda, Meiji Seika Pharma deal

...co-promotion rights to Rozerem ramelteon to treat insomnia. Meiji will begin promotional activities for the melatonin...
BioCentury | Jun 9, 2014
Clinical News

Hetlioz tasimelteon regulatory update

...an MAA for Hetlioz tasimelteon to treat non-24 hour sleep wake disorder. FDA approved the melatonin...
Items per page:
1 - 10 of 113